Of these, we highlight sarilumab and satralizumab as exhibiting the most potential as drug repurposing candidates for depression because they target IL6R, which was identified as the gene exhibiting the strongest potential as a target gene according to the functional annotation scoring system and the validation conducted using the ClinicalTrials.gov and PubMed databases (Table 3). This evidence concerns the gene IL6R and major depressive disorder.